| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Rheumatology, Department of Medicine, Research Institute of the McGill University Health Center, McGill University, Montreal, Quebec, Canada; and
Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL 60637
Anti-phospholipid Ab (aPL) are a heterogeneous group of autoantibodies directed against various combinations of phospholipids (PL) and PL-binding proteins. Lupus anticoagulant (LA) Ab, a subset of aPL, exhibit anticoagulant properties in vitro, but are procoagulant in vivo. Most LA Ab are specific for either 
2-glycoprotein I (2GPI) or prothrombin (PT), two PL-binding proteins. We have previously shown that 2GPI and 2GPI-dependent aPL bind specifically to apoptotic, but not viable, thymocytes. In this study, we demonstrate that PT, like 2GPI, binds selectively to the surface of apoptotic, but not viable, Jurkat cells. Furthermore, PT supports the binding of systemic lupus erythematosus-derived polyclonal and murine monoclonal LA Ab to apoptotic cells. Two LA mAb, which differed dramatically in their relative affinities for PT, were studied. Although one mAb (29J3-62) had a high affinity for PT alone, the other (29I4-24) showed minimal reactivity with PT alone and required PL for elevated binding. Monovalent fragments of 29I4-24 reacted with PL-bound PT with high affinity, suggesting that this mAb recognizes a PL-dependent epitope. Despite these differences, PT-dependent binding of both mAb to apoptotic cells was 30-fold greater than that to viable cells. Moreover, binding of PT to apoptotic cells was, itself, increased in the presence of bivalent, but not monovalent, forms of either mAb. In summary, our data demonstrate the following: 1) specific binding of PT to apoptotic cells, an effect enhanced by PT-dependent LA Ab; 2) heterogeneity of PT-dependent LA Ab; and 3) potential pathogenicity of Ab of either low or high affinity for PT.
This article has been cited by other articles:
|
|
 |
|
  T. Kawakami, M. Yamazaki, M. Mizoguchi, and Y. Soma Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa Rheumatology, May 1, 2009; 48(5): 508 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawakami, M. Yamazaki, M. Mizoguchi, and Y. Soma Antiphosphatidylserine-Prothrombin Complex Antibodies in 3 Patients With Behcet Disease Involving Superficial Vein Thrombophlebitis Arch Dermatol, February 1, 2009; 145(2): 171 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawakami, S. Ooka, M. Mizoguchi, Y. Soma, and M. Yamazaki Remission of Hepatitis B Virus-Related Cryoglobulinemic Vasculitis with Entecavir Ann Intern Med, December 16, 2008; 149(12): 911 - 912. [Full Text] [PDF]
|
|
|
|
|
|
T. Kawakami, M. Yamazaki, K. Kawasaki, M. Mizoguchi, and Y. Soma Therapeutic Effect of Argatroban on Rheumatoid Vasculitis With Antiphosphatidylserine-Prothrombin Complex Antibody Arch Dermatol, August 1, 2008; 144(8): 1075 - 1076. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Horita, K. Ichikawa, H. Kataoka, S. Yasuda, T. Atsumi, and T. Koike Human monoclonal antibodies against the complex of phosphatidylserine and prothrombin from patients with the antiphospholipid antibodies Lupus, July 1, 2007; 16(7): 509 - 516. [Abstract] [PDF]
|
|
|
|
|
|
H. S. Cheong, S. O. Lee, C.-B. Choi, Y.-K. Sung, H. D. Shin, and S.-C. Bae MERTK polymorphisms associated with risk of haematological disorders among Korean SLE patients Rheumatology, February 1, 2007; 46(2): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis Current concepts on the pathogenesis of the antiphospholipid syndrome Blood, January 15, 2007; 109(2): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fan, V. A. Patel, A. Longacre, and J. S. Levine Abnormal regulation of the cytoskeletal regulator Rho typifies macrophages of the major murine models of spontaneous autoimmunity J. Leukoc. Biol., January 1, 2006; 79(1): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Trouw, S. C. Nilsson, I. Goncalves, G. Landberg, and A. M. Blom C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation J. Exp. Med., June 20, 2005; 201(12): 1937 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Longacre, J. S. Koh, K. K-H. Hsiao, H. Gilligan, H. Fan, V. A. Patel, and J. S. Levine Macrophages from lupus-prone MRL mice are characterized by abnormalities in Rho activity, cytoskeletal organization, and adhesiveness to extracellular matrix proteins J. Leukoc. Biol., November 1, 2004; 76(5): 971 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Radic, T. Marion, and M. Monestier Nucleosomes Are Exposed at the Cell Surface in Apoptosis J. Immunol., June 1, 2004; 172(11): 6692 - 6700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fan, A. Longacre, F. Meng, V. Patel, K. Hsiao, J. S. Koh, and J. S. Levine Cytokine Dysregulation Induced by Apoptotic Cells Is a Shared Characteristic of Macrophages from Nonobese Diabetic and Systemic Lupus Erythematosus-Prone Mice J. Immunol., April 15, 2004; 172(8): 4834 - 4843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. C. Dieker, J. van der Vlag, and J. H. M. Berden Deranged removal of apoptotic cells: its role in the genesis of lupus Nephrol. Dial. Transplant., February 1, 2004; 19(2): 282 - 285. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
